Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

d-glucuronyl C5-epimerase cell type specifically affects angiogenesis pathway in different prostate cancer cells

Authors: Eugenia E. Rosenberg, Tatiana Y. Prudnikova, Eugene R. Zabarovsky, Vladimir I. Kashuba, Elvira V. Grigorieva

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

d-glucuronyl C5-epimerase (GLCE) is involved in breast and lung carcinogenesis as a potential tumor suppressor gene, acting through inhibition of tumor angiogenesis and invasion/metastasis pathways. However, in prostate tumors, increased GLCE expression is associated with advanced disease, suggesting versatile effects of GLCE in different cancers. To investigate further the potential cancer-promoting effect of GLCE in prostate cancer, GLCE was ectopically re-expressed in morphologically different LNCaP and PC3 prostate cancer cells. Transcriptional profiles of normal PNT2 prostate cells, LNCaP, PC3 and DU145 prostate cancer cells, and GLCE-expressing LNCaP and PC3 cells were determined. Comparative analysis revealed the genes whose expression was changed in prostate cancer cells compared with normal PNT2 cells, and those differently expressed between the cancer cell lines (ACTA2, IL6, SERPINE1, TAGLN, SEMA3A, and CDH2). GLCE re-expression influenced mainly angiogenesis-involved genes (ANGPT1, SERPINE1, IGF1, PDGFB, TNF, IL8, TEK, IFNA1, and IFNB1) but in a cell type-specific manner (from basic deregulation of angiogenesis in LNCaP cells to significant activation in PC3 cells). Invasion/metastasis pathway was also affected (MMP1, MMP2, MMP9, S100A4, ITGA1, ITGB3, ERBB2, and FAS). The obtained results suggest activation of angiogenesis as a main molecular mechanism of pro-oncogenic effect of GLCE in prostate cancer. GLCE up-regulation plus expression pattern of a panel of six genes, discriminating morphologically different prostate cancer cell sub-types, is suggested as a potential marker of aggressive prostate cancer.
Literature
1.
Li JP. Glucuronyl C5-epimerase: an enzyme converting glucuronic acid to iduronic acid in heparan sulfate/heparin biosynthesis. Progress in Molecular Biology and Translational Science. Z. Lijuan (Ed.): Academic Press; 2010. V. 93, pp. 59–78.
2.
Sheng J, Xu Y, Dulaney SB, Huang X, Liu J. Uncovering biphasic catalytic mode of C5-epimerase in heparan sulfate biosynthesis. J Biol Chem. 2012;287:20996–1002.PubMedCentralPubMedCrossRef
3.
Catlow KR, Deakin JA, Wei Z, Delehedde M, Fernig DG, Gherardi E, et al. Interactions of hepatocyte growth factor/scatter factor with various glycosaminoglycans reveal an important interplay between the presence of iduronate and sulfate density. J Biol Chem. 2008;283:5235–48.PubMedCrossRef
4.
Jia J, Maccarana M, Zhang X, Bespalov M, Lindahl U, Li JP. Lack of l-iduronic acid in heparan sulfate affects interaction with growth factors and cell signaling. J Biol Chem. 2009;284:15942–50.PubMedCentralPubMedCrossRef
5.
Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol. 2011;209:139–51.PubMedCrossRef
6.
Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, et al. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J. 2012;279:1177–97.PubMedCrossRef
7.
Raedts J, Kengen SW, van der Oost J. Occurrence of l-iduronic acid and putative d-glucuronyl C5-epimerases in prokaryotes. Glycoconj J. 2011;28:57–66.PubMedCentralPubMedCrossRef
8.
Raedts J, Lundgren M, Kengen SW, Li JP, van der Oost J. A novel bacterial enzyme with d-glucuronyl C5-epimerase activity. J Biol Chem. 2013;288:24332–9.PubMedCrossRef
9.
Dejima K, Takemura M, Nakato E, Peterson J, Hayashi Y, Kinoshita-Toyoda A, Toyoda H, Nakato H. Analysis of Drosophila glucuronyl C-5 epimerase: implications for developmental roles of heparan sulfate sulfation compensation and 2-O sulfated glucuronic acid. J Biol Chem. 2013 Oct 16. Epub ahead of print.
10.
Reijmers RM, Vondenhoff MF, Roozendaal R, Kuil A, Li JP, Spaargaren M, et al. Impaired lymphoid organ development in mice lacking the heparan sulfate modifying enzyme glucuronyl C5-epimerase. J Immunol. 2010;184:3656–64.PubMedCrossRef
11.
Eshchenko TY, Rykova VI, Chernakov AE, Sidorov SV, Grigorieva EV. Expression of different proteoglycans in human breast tumors. Biochem Mosc. 2007;72:1016–20.CrossRef
12.
Grigorieva E, Eshchenko T, Rykova VI, Chernakov A, Zabarovsky E, Sidorov SV. Decreased expression of human d-glucuronyl C5-epimerase in breast cancer. Int J Cancer. 2008;122:1172–6.PubMedCrossRef
13.
Grigorieva EV, Prudnikova TY, Domanitskaya NV, Mostovich LA, Pavlova TV, Kashuba VI, et al. d-glucuronyl C5-epimerase suppresses small-cell lung cancer cell proliferation in vitro and tumour growth in vivo. Br J Cancer. 2011;105:74–82.PubMedCentralPubMedCrossRef
14.
Prudnikova TY, Mostovich LA, Domanitskaya NV, Pavlova TV, Kashuba VI, Zabarovsky ER, et al. Antiproliferative effect of d-glucuronyl C5-epimerase in human breast cancer cells. Cancer Cell Int. 2010;10:27.PubMedCentralPubMedCrossRef
15.
Prudnikova TY, Soulitzis N, Kutsenko OS, Mostovich LA, Haraldson K, Ernberg I, Kashuba VI, Spandidos DA, Zabarovsky ER, Grigorieva EV. Heterogeneity of d-glucuronyl C5-epimerase expression and epigenetic regulation in prostate cancer. Cancer Medicine 2013; doi:10.​1002/​cam4.​108
16.
Boyd LK, Mao X, Lu YJ. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol. 2012;9:652–64.PubMedCrossRef
17.
Faratian D, Christiansen J, Gustavson M, Jones C, Scott C, Um I, et al. Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence. J Vis Exp. 2011;56:e3334.PubMed
18.
Shen-Orr SS, Tibshirani R, Khatri P, Bodian DL, Staedtler F, Perry NM, et al. Cell type-specific gene expression differences in complex tissues. Nat Methods. 2010;7:287–9.PubMedCentralPubMedCrossRef
19.
Chen X, Xu S, McClelland M, Rahmatpanah F, Sawyers A, Jia Z, et al. An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account. PLoS One. 2012;7:e45178.PubMedCentralPubMedCrossRef
20.
Singh AP, Bafna S, Chaudhary K, Venkatraman G, Smith L, Eudy JD, et al. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett. 2008;259:28–38.PubMedCentralPubMedCrossRef
21.
Feldhammer M, Uetani N, Miranda-Saavedra D, Tremblay ML. PTP1B: A simple enzyme for a complex world. Critical Rev. Biochem. Mol. Biol. 2013; Jul 23.
22.
Lafitte M, Moranvillier I, Garcia S, Peuchant E, Iovanna J, Rousseau B, et al. FGFR3 has tumor suppressor properties in cells with epithelial phenotype. Mol Cancer. 2013;12:83.PubMedCentralPubMedCrossRef
23.
Luo Y, Kaz AM, Kanngurn S, Welsch P, Morris SM, Wang J, et al. NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer. PLoS Genet. 2013;9:e1003552.PubMedCentralPubMedCrossRef
24.
Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res. 2013;119:191–419.PubMedCrossRef
25.
Zhang B, Chen H, Zhang L, Dakhova O, Zhang Y, Lewis MT, Creighton CJ, Ittmann MM, Xin L. A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis. Oncogene 2013; Jul 15.
26.
Mostovich LA, Prudnikova TY, Kondratov AG, Gubanova NV, Kharchenko OA, Kutsenko OS, et al. The TCF4/β-catenin pathway and chromatin structure cooperate to regulate d-glucuronyl C5-epimerase expression in breast cancer. Epigenetics. 2012;7:930–9.PubMedCentralPubMedCrossRef
27.
Ghiselli G, Agrawal A. The human d-glucuronyl C5-epimerase gene is transcriptionally activated through the beta-catenin-TCF4 pathway. Biochem J. 2005;390:493–9.PubMedCentralPubMedCrossRef
28.
Prudnikova TY, Mostovich LA, Kashuba VI, Ernberg I, Zabarovsky ER, Grigorieva EV. miRNA-218 contributes to the regulation of d-glucuronyl C5-epimerase expression in normal and tumor breast tissues. Epigenetics. 2012;7:1109–14.PubMedCentralPubMedCrossRef
29.
Small EM, Sutherland LB, Rajagopalan KN, Wang S, Olson EN. MicroRNA-218 regulates vascular patterning by modulation of Slit-Robo signaling. Circulation Res. 2010;107:1336–44.PubMedCentralPubMedCrossRef
Metadata
Title
d-glucuronyl C5-epimerase cell type specifically affects angiogenesis pathway in different prostate cancer cells
Authors
Eugenia E. Rosenberg
Tatiana Y. Prudnikova
Eugene R. Zabarovsky
Vladimir I. Kashuba
Elvira V. Grigorieva
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1423-6

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

Meta-analysis: eating frequency and risk of colorectal cancer

Research Article

The volume and duration of wound drainage are independent prognostic factors for breast cancer

Research Article

Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients

Research Article

Matrilysin-2 expression in colorectal cancer is associated with overall survival of patients

Research Article

Study on the association between the Arg194Trp polymorphism in the XRCC1 gene and the risk of hematological malignancies

Research Article

The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits